Progress in active specific immunotherapy of prostate cancer

Citation
Ba. Tjoa et Gp. Murphy, Progress in active specific immunotherapy of prostate cancer, SEM SURG ON, 18(1), 2000, pp. 80-87
Citations number
79
Categorie Soggetti
Oncology
Journal title
SEMINARS IN SURGICAL ONCOLOGY
ISSN journal
87560437 → ACNP
Volume
18
Issue
1
Year of publication
2000
Pages
80 - 87
Database
ISI
SICI code
8756-0437(200001/02)18:1<80:PIASIO>2.0.ZU;2-3
Abstract
Treatments available for metastatic prostate cancer have failed to demonstr ate significant curative potential. Current efforts are now directed toward s developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system components to kill cancer cells. This review discusses progress in active s pecific immunotherapeutic approaches as potential alternative methods in th e treatment of metastatic prostate cancer. Various methods of augmenting th e immune response against prostate cancer are discussed including systemic cytokine adjuvant therapy, cytokine gene transduced tumor vaccines, non-ant igen specific immunization, DNA and peptide vaccines plus adjuvants, as wel l as dendritic cell-based cancer vaccines. (C) 2000 Wiley-Liss, Inc.